Incyte (INCY) Tops Q2 EPS by 36c
Incyte (NASDAQ: INCY) reported Q2 EPS of $1.24, $0.36 better than the analyst estimate of $0.88. Revenue for the quarter came in at $688 million versus the consensus estimate of $612.14 million.
2020 Financial Guidance
The Company has reaffirmed its full year 2020 financial guidance, as detailed below. The R&D expense guidance excludes $805 million of upfront consideration paid under the MorphoSys collaboration. The financial guidance also excludes the impact of any potential future strategic transactions.
All data in millions |
| Current |
| Previous |
Jakafi net product revenues |
| $1,880 - $1,950 |
| Unchanged |
Iclusig net product revenues |
| $100 - $105 |
| Unchanged |
GAAP Cost of product revenues |
| $130 - $135 |
| Unchanged |
Non-GAAP Cost of product revenues1 |
| $107 - $112 |
| Unchanged |
GAAP Research and development expenses |
| $1,210 - $1,280 |
| Unchanged |
Non-GAAP Research and development expenses2 |
| $1,079 - $1,149 |
| Unchanged |
GAAP Selling, general and administrative expenses |
| $505 - $535 |
| Unchanged |
Non-GAAP Selling, general and administrative expenses2 |
| $447 - $477 |
| Unchanged |
GAAP Change in fair value of acquisition-related contingent consideration |
| $25 - $27 |
| Unchanged |
Non-GAAP Change in fair value of acquisition-related contingent consideration3 |
| $0 |
| Unchanged |
For earnings history and earnings-related data on Incyte (INCY) click here.